



(51) International Patent Classification:
C12Q 1/6883 (2018.01)

(21) International Application Number:
PCT/SG2021/050063

(22) International Filing Date:
05 February 2021 (05.02.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10202001048U 05 February 2020 (05.02.2020) SG

(71) Applicants: **AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH** [SG/SG]; 1 Fusionopolis Way, #20-10 Connexis North Tower, Singapore 138632 (SG). **SINGAPORE HEALTH SERVICES PTE LTD** [SG/SG]; 31 Third Hospital Avenue, #03-03 Bowyer Block C, Singapore 168753 (SG).

(72) Inventors: **FOO, Jia Nee**; c/o Lee Kong Chian School of Medicine/Nanyang Technological University Singapore and Genome Institute of Singapore, 11 Mandalay Road, Clinical Sciences Building level 11, Singapore 308232

(SG). **LIU, Jianjun**; c/o Genome Institute of Singapore, 60 Biopolis Street, Genome #02-01, Singapore 138672 (SG). **TAN, Eng-King**; c/o National Neuroscience Institute, Singapore General Hospital, The Academia, 20 College Road, Medical Offices Level 4, Singapore 169856 (SG).


(74) Agent: **SPRUSON & FERGUSON (ASIA) PTE LTD**; P.O. Box 1531, Robinson Road Post Office, Singapore 903031 (SG).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

(54) Title: BIOMARKERS FOR RISK PREDICTION OF PARKINSON'S DISEASE

Figure 1



(57) Abstract: The present invention refers to a method of identifying whether a subject is at risk of developing PD (PD), whether a subject is suffering from PD, or whether a subject is in need of early therapeutic intervention for PD, the method comprising detecting the presence of a genetic variant at the loci of one or more genes selected from the group consisting of *SV2C*, *WBSCR17*, *PARK16*, *ITPKB*, *MCCC1*, *SNCA*, *FAM47E-SCARB2*, *FYN*, *DLG2*, *LRRK2*, *RIT2* and combinations thereof in a sample obtained from the subject, wherein the presence of one or more genetic variants identifies that the subject is at risk of developing PD, the subject is suffering from PD, or the subject is in need of early therapeutic intervention for PD. Also, described herein are a method of determining the prognosis of a subject with PD or a subject at risk of developing PD and a method for calculating a polygenic risk score (PRS) of a subject of developing PD. Further, described herein are biomarkers and kits for PD.

[Continued on next page]

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*